Q-omics provides the consensus-scored TPT1-AS1 profile across patient tissues and cancer cell-line models. TPT1-AS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TPT1-AS1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TPT1-AS1 RNA expression shows 20,361 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, KICH, and ACC as cancer lineages where TPT1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPT1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPT1-AS1 survival associations across molecular data types. TPT1-AS1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPT1-AS1 RNA expression–survival associations across cancer types. High TPT1-AS1 expression shows unfavorable associations in BLCA, OV and COAD, but favorable associations in PAAD, THYM and READ. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify PAAD as the clearest survival context for TPT1-AS1 RNA expression.
This table summarizes TPT1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TPT1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPT1-AS1 shows lower tumor expression in KICH, UCEC and BLCA and higher tumor expression in HNSC, LIHC and KIRC. The KICH box plot shows higher TPT1-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.120, t-test p < 0.001).
This table shows molecular features associated with TPT1-AS1 in patient tissues and cancer cell lines. In patient samples, TPT1-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
